%0 Journal Article %1 Kube.2008 %A Kube, Dieter %A Hua, Thanh-Duc %A Bonin, Frederike von %A Schoof, Nils %A Zeynalova, Samira %A Klöss, Marita %A Gocht, Daniela %A Potthoff, Bernd %A Tzvetkov, Mladen %A Brockmöller, Jürgen %A Loeffler, Markus %A Pfreundschuh, Michael %A Trümper, Lorenz %D 2008 %J Clinical cancer research : an official journal of the American Association for Cancer Research %K IMISE-Publikationen %N 12 %P 3777–3784 %T Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study %V 14 %X PURPOSE\r\nCurrent chemotherapy can achieve high response rates in aggressive non-Hodgkin's lymphoma (NHL), but the factors that influence regression and survival remain unknown. The present exploratory study tested the hypothesis whether interleukin-10 (IL-10) polymorphisms predict clinical outcome, leukocytopenia, or infectivity during therapy. IL-10 was chosen because immune alterations are a major risk factor for NHL, and IL-10 is a cytokine involved in inflammatory processes associated with clinical outcome.\r\nEXPERIMENTAL DESIGN\r\nFive hundred patients with aggressive NHL treated with CHOP/CHOEP were analyzed for IL-10 gene polymorphisms, including distal loci -7400InDel, -6752AT (rs6676671), and -6208CG (rs10494879) in comparison with proximal loci -3538AT (rs1800890), -1087AG (rs1800896), and -597AC (rs1800872) according to the incidence and outcome of the lymphoma.\r\nRESULTS\r\nNo differences in allele frequencies or haplotypes were found comparing a cohort of patients with aggressive NHL/diffuse large B-cell lymphoma with a healthy control group. Patients with aggressive NHL characterized by IL-10(-7400DelDel) had shorter overall survival periods compared with the other genotypes (P = 0.004). The 3-year rate is 43.4\% for IL-10(-7400DelDel) and 73.4\% for IL-10(-7400InIn) and IL-10(-7400InDel) together. A significant increased risk for event-free survival is found for carriers of the genotype IL-10(-6752TT-6208CC-3538AA) (P = 0.047). Multivariate analysis of IL-10(-7400) gene variation in relation to overall survival adjusted to international prognostic index revealed a relative risk of 1.9 for carriers of IL-10(-7400DelDel) (P = 0.037). No associations were found analyzing diffuse large B-cell lymphoma patients separately.\r\nCONCLUSION\r\nOur results indicate that IL-10 gene variations could be associated to the clinical course of aggressive NHL, which points out the importance of host factors and respective genetic elements for treatment response.

@article{Kube.2008, abstract = {PURPOSE\r\nCurrent chemotherapy can achieve high response rates in aggressive non-Hodgkin's lymphoma (NHL), but the factors that influence regression and survival remain unknown. The present exploratory study tested the hypothesis whether interleukin-10 (IL-10) polymorphisms predict clinical outcome, leukocytopenia, or infectivity during therapy. IL-10 was chosen because immune alterations are a major risk factor for NHL, and IL-10 is a cytokine involved in inflammatory processes associated with clinical outcome.\r\nEXPERIMENTAL DESIGN\r\nFive hundred patients with aggressive NHL treated with CHOP/CHOEP were analyzed for IL-10 gene polymorphisms, including distal loci -7400InDel, -6752AT (rs6676671), and -6208CG (rs10494879) in comparison with proximal loci -3538AT (rs1800890), -1087AG (rs1800896), and -597AC (rs1800872) according to the incidence and outcome of the lymphoma.\r\nRESULTS\r\nNo differences in allele frequencies or haplotypes were found comparing a cohort of patients with aggressive NHL/diffuse large B-cell lymphoma with a healthy control group. Patients with aggressive NHL characterized by IL-10(-7400DelDel) had shorter overall survival periods compared with the other genotypes (P = 0.004). The 3-year rate is 43.4\% for IL-10(-7400DelDel) and 73.4\% for IL-10(-7400InIn) and IL-10(-7400InDel) together. A significant increased risk for event-free survival is found for carriers of the genotype IL-10(-6752TT-6208CC-3538AA) (P = 0.047). Multivariate analysis of IL-10(-7400) gene variation in relation to overall survival adjusted to international prognostic index revealed a relative risk of 1.9 for carriers of IL-10(-7400DelDel) (P = 0.037). No associations were found analyzing diffuse large B-cell lymphoma patients separately.\r\nCONCLUSION\r\nOur results indicate that IL-10 gene variations could be associated to the clinical course of aggressive NHL, which points out the importance of host factors and respective genetic elements for treatment response.}, added-at = {2014-10-15T15:04:08.000+0200}, author = {Kube, Dieter and Hua, Thanh-Duc and Bonin, Frederike von and Schoof, Nils and Zeynalova, Samira and Klöss, Marita and Gocht, Daniela and Potthoff, Bernd and Tzvetkov, Mladen and Brockmöller, Jürgen and Loeffler, Markus and Pfreundschuh, Michael and Trümper, Lorenz}, biburl = {https://www.bibsonomy.org/bibtex/2db0db6e4d71c4a95dbad4bdb8e7c44cb/drtester}, interhash = {9f63624807e28f592dc97b33b4b760cc}, intrahash = {db0db6e4d71c4a95dbad4bdb8e7c44cb}, journal = {Clinical cancer research : an official journal of the American Association for Cancer Research}, keywords = {IMISE-Publikationen}, number = 12, pages = {3777–3784}, timestamp = {2014-12-03T00:08:46.000+0100}, title = {Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study}, volume = 14, year = 2008 }